Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
The U.S. Food and Drug Administration (FDA) has approved a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line therapy for adults with inoperable malignant pleural mesothelioma (MPM), a rare but aggressive ... Read more
Eureka Therapeutics has started enrolling adults with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, in a Phase 1/2 trial of its investigational ET140203 T-cell therapy. ... Read more
The U.S. Food and Drug Administration (FDA) has accepted and given priority review to AstraZeneca‘s application requesting a new dosing regimen for Imfinzi (durvalumab) to treat certain non-small cell lung cancer (NSCLC) and ... Read more
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for ... Read more
A combination of Vaccinex‘s investigational antibody pepinemab and the immune checkpoint inhibitor Bavencio (avelumab) was well-tolerated and showed signs of lasting anti-tumor activity in patients with advanced non-small cell lung ... Read more